Cells from patients' own blood spur cancer remissions

 

Pennsylvania

Nine leukemia patients are cancer-free after being treated with genetically-altered versions of their own immune cells, giving strength to a promising new approach for treating the blood cancer.

The trial of 12 patients, two of them children, bolsters findings from 2011. Then, scientists from the University of Pennsylvania in Philadelphia reported that two of the first three patients treated showed no traces of the malignancy after getting the therapy. Today's results were presented at the American Society of Hematology's annual meeting in Atlanta.

For Walter Keller, 59, who had failed every other treatment for his chronic lymphocytic leukemia diagnosed in 1996, the regimen meant he's been in remission since his treatment in April. Before the therapy, "I thought I had a year to live," he said.

"I feel better than I have in a long, long time," said Keller, of Upland, Calif., in a telephone interview. "I'm excited because I think this will help a lot of people."

The approach developed by University of Pennsylvania scientists has since been acquired by Novartis.

The scientists, led by Carl June, a professor of pathology and laboratory medicine at the Abramson Cancer Center at the University of Pennsylvania and a study author, used genetic engineering to manipulate white blood cells extracted from the patients. The researchers reprogrammed the cells to specifically target the leukemia cells and reinjected them into the patients.

CLL is a slow-growing cancer that starts from white blood cells in the bone marrow and interferes with the production of healthy blood cells. The condition leads to complications such as immune deficiencies and swollen lymph nodes. The disease strikes about 16,000 adults each year and 4,600 die from it, according to the American Cancer Society.

The disease is treated with chemotherapy. Another approach is bone marrow transplant in which chemotherapy is first given to kill diseased cells then replaced with healthy ones from bone marrow extracted from the patient or a donor.

Keller underwent chemotherapy and then a stem cell transplant in 1998 and 1999. He was in remission for 5 and a half years. He then underwent a different chemotherapy regimen and got a second stem cell transplant. The cancer came back again in 2010, and he had no options left. He was one of 10 adult patients treated so far.

"No patient who had complete remission has lost it," said Keller's doctor, David Porter, director of blood and marrow transplantation at the University of Pennsylvania's Abramson Cancer Center. "It's unusual to have a treatment that can work to this magnitude and until now, this duration."

Two of the original three patients treated have maintained their remissions over 2 years later. The scientists found signs of the designer blood cells still circulating in their bodies.

Two girls, ages 7 and 10, were also treated for a fast- growing blood cancer that affects children called acute lymphoblastic leukemia. Both had been treated and had then relapsed, said Stephan Grupp, director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia. He presented research on their care at the hematology meeting.

One of the girls has been in complete remission in the 8 months since her treatment. The other had a remission of "a few months" before relapsing again, Grupp said. The younger girl had severe side-effects.

Previous studies have documented severe, flu-like illness in patients treated with their pumped-up immune cells. The 7- year-old's severe reaction helped explain what was happening, Grupp said. Her levels of an inflammatory protein called IL-6 were very high, 998 times her ordinary level. His group treated her with Roche's Actemra, approved for rheumatoid arthritis, which targets the protein. Because her levels of another inflammatory protein called TNF were high, she was also treated with Amgen and Pfizer's Enbrel.

"The next morning, she was dramatically better," Grupp said.

Her reaction suggests that the illness caused by the treatment is the result of an overactive immune system. Previously it wasn't clear what had caused the reactions, since tumors also release poisons when they're broken up to be cleared from the system.

Three adults being dosed with their own altered immune cells were also treated with Actemra, which lowered high fevers, restored abnormally low blood pressure, and allowed patients to easily breathe again.

"Everyone says I look good," said Keller, who also experienced flu symptoms after the treatment. "I guess I looked like crap before."

Novartis funded a $20 million research center at the University of Pennsylvania in Philadelphia, as well as paying an undisclosed amount of money for rights to the therapy in August. The therapy will be called CTL019 by the drugmaker.

Today's research was funded by the Leukemia & Lymphoma Society, the Alliance for Cancer Gene Therapy and the National Institutes of Health.

Start your day with The Independent, sign up for daily news emails
Have you tried new the Independent Digital Edition apps?
ebooks
ebooksAn introduction to the ground rules of British democracy
Arts and Entertainment
Ben Stiller as Derek Zoolander in the leaked trailer for Zoolander 2
film
Sport
footballArsenal take the Community Shield thanks to a sensational strike from Alex Oxlade-Chamberlain
Arts and Entertainment
Gemma Chan as synth Anita in Humans
film
News
Keeping it friendly: Tom Cruise on ‘The Daily Show’ with Jon Stewart
people
Arts and Entertainment
Ensemble cast: Jamie McCartney with ‘The Great Wall of Vagina’
artBritish artist Jamie McCartney explains a work that is designed to put women's minds at rest
News
Republican Presidential Candidate Donald Trump
people
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Recruitment Genius: IT Support Engineer

£18000 - £26000 per annum: Recruitment Genius: This is an opportunity for an I...

Recruitment Genius: Project Assistant

£17000 per annum: Recruitment Genius: They are a leading company in the field ...

Recruitment Genius: DBA Developer - SQL Server

£30000 - £35000 per annum: Recruitment Genius: This is an exciting opportunity...

Recruitment Genius: Office Manager

£26041 - £34876 per annum: Recruitment Genius: There has never been a more exc...

Day In a Page

Turkey-Kurdish conflict: Obama's deal with Ankara is a betrayal of Syrian Kurds and may not even weaken Isis

US betrayal of old ally brings limited reward

Since the accord, the Turks have only waged war on Kurds while no US bomber has used Incirlik airbase, says Patrick Cockburn
VIPs gather for opening of second Suez Canal - but doubts linger over security

'A gift from Egypt to the rest of the world'

VIPs gather for opening of second Suez Canal - but is it really needed?
Jeremy Corbyn dresses abysmally. That's a great thing because it's genuine

Jeremy Corbyn dresses abysmally. That's a great thing because it's genuine

Fashion editor, Alexander Fury, applauds a man who clearly has more important things on his mind
The male menopause and intimations of mortality

Aches, pains and an inkling of mortality

So the male menopause is real, they say, but what would the Victorians, 'old' at 30, think of that, asks DJ Taylor
Man Booker Prize 2015: Anna Smaill - How can I possibly be on the list with these writers I have idolised?

'How can I possibly be on the list with these writers I have idolised?'

Man Booker Prize nominee Anna Smaill on the rise of Kiwi lit
Bettany Hughes interview: The historian on how Socrates would have solved Greece's problems

Bettany Hughes interview

The historian on how Socrates would have solved Greece's problems
Art of the state: Pyongyang propaganda posters to be exhibited in China

Art of the state

Pyongyang propaganda posters to be exhibited in China
Mildreds and Vanilla Black have given vegetarian food a makeover in new cookbooks

Vegetarian food gets a makeover

Long-time vegetarian Holly Williams tries to recreate some of the inventive recipes in Mildreds and Vanilla Black's new cookbooks
The haunting of Shirley Jackson: Was the gothic author's life really as bleak as her fiction?

The haunting of Shirley Jackson

Was the gothic author's life really as bleak as her fiction?
Bill Granger recipes: Heading off on holiday? Try out our chef's seaside-inspired dishes...

Bill Granger's seaside-inspired recipes

These dishes are so easy to make, our chef is almost embarrassed to call them recipes
Ashes 2015: Tourists are limp, leaderless and distinctly UnAustralian

Tourists are limp, leaderless and distinctly UnAustralian

A woefully out-of-form Michael Clarke embodies his team's fragile Ashes campaign, says Michael Calvin
Blairites be warned, this could be the moment Labour turns into Syriza

Andrew Grice: Inside Westminster

Blairites be warned, this could be the moment Labour turns into Syriza
HMS Victory: The mystery of Britain's worst naval disaster is finally solved - 271 years later

The mystery of Britain's worst naval disaster is finally solved - 271 years later

Exclusive: David Keys reveals the research that finally explains why HMS Victory went down with the loss of 1,100 lives
Survivors of the Nagasaki atomic bomb attack: Japan must not abandon its post-war pacifism

'I saw people so injured you couldn't tell if they were dead or alive'

Nagasaki survivors on why Japan must not abandon its post-war pacifism
Jon Stewart: The voice of Democrats who felt Obama had failed to deliver on his 'Yes We Can' slogan, and the voter he tried hardest to keep onside

The voter Obama tried hardest to keep onside

Outgoing The Daily Show host, Jon Stewart, became the voice of Democrats who felt the President had failed to deliver on his ‘Yes We Can’ slogan. Tim Walker charts the ups and downs of their 10-year relationship on screen